Results 161 to 170 of about 23,300 (302)

Depth of Invasion as a Predictor of Contralateral Nodal Metastasis in Lateralized Oral Tongue Squamous Cell Carcinomas

open access: yesHead &Neck, EarlyView.
ABSTRACT Background This study evaluates the impact of depth of invasion (DOI) on risk of contralateral neck nodal disease (CND) in lateralized oral tongue squamous cell carcinoma (SCC). Methods Retrospective review was conducted using a tertiary care institutional database from 1998 to 2021.
Jake Sims   +7 more
wiley   +1 more source

Recurrence Risk in Lateralized Floor of Mouth Carcinoma: Depth of Invasion Versus Midline Distance

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Contralateral nodal recurrence in lateralized floor‐of‐mouth squamous cell carcinoma (OSCC) remains difficult to predict, and objective preoperative parameters to guide contralateral neck management in tumors without midline crossing are lacking.
Jannik Ketschau   +10 more
wiley   +1 more source

Can We Compare Adverse Events' Attributable Risk Using a Self-Controlled Case Series Design for Vaccine Safety? A Guillain-Barré Syndrome Use Case. [PDF]

open access: yesInfect Dis Ther
Liang C   +9 more
europepmc   +1 more source

SCCS - Scientific Opinion on Tea Tree Oil (CAS/EC No. 68647-73-4 /285-377-1) [PDF]

open access: yes
SCCS External Experts: E. Benfenati, N. Cabaton, E. Corsini, Ch. Delmaar, A. Koutsodimou, H. Louro, W. Uter, N. von Goetz.Adopted on: 30 October 2025.The SCCS concludes the following: 1.
Scientific Committee on Consumer Safety (SCCS)
core  

Immunotherapy for Head and Neck Cutaneous Squamous Cell Carcinoma with Perineural Spread: A Systematic Review

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Immunotherapy is increasingly used for head and neck cutaneous squamous cell carcinoma (cSCC) with perineural spread (PNS), though outcomes remain poorly defined. Methods A systematic review was conducted according to PRISMA and MOOSE guidelines.
Jai Paris   +4 more
wiley   +1 more source

Real‐World Outcomes of Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Oral Cavity, Pharynx, and Larynx: An Australian Population‐Based Study

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Nivolumab is an immune checkpoint inhibitor used for recurrent/metastatic squamous cell carcinoma (SCC) of the oral cavity, pharynx, and larynx; yet Australian real‐world evidence remains limited. Methods A retrospective cohort study was conducted using linked Pharmaceutical Benefits Scheme dispensing and National Death Index ...
Phoebe L. Sault   +3 more
wiley   +1 more source

SCCS Opinion on Butylparaben (CAS No. 94-26-8, EC No. 202-318-7) - Children's exposure

open access: yes
SCCS External Experts: E. Benfentati, N. Cabaton, E. Corsini, Ch. Delmaar, A. Koutsodimou, H. Louro , W. Uter, N. von Goetz.Adopted on: 30 April 2025The SCCS concludes the following: 1.
European Commission. Scientific Committee on Consumer Safety (SCCS)
core  

Home - About - Disclaimer - Privacy